Morning Industry Symposium:
Time to start CDK4&6 inhibition in EBC: Verzenio in HR+ HER2- node positive EBC at high risk of recurrence
Supported by Lilly
Saturday, October 15, 2022 Hall B (Great Hall 2)
07:30-08:30
Breakfast will be served from 07:00-07:30, half an hour prior to the start of the session.
Admission to this symposium is included as part of the congress registration.
| Chairperson: | Richard de Boer, Melbourne, Australia |
| 07:30-07:50 | Verzenio’s efficacy in node positive early breast cancer at high risk of recurrence Alistair Ring, London, UK |
| 07:50-08:10 | Verzenio safety and tolerability: Learnings from MonarchE and food tolerability study Fran Boyle, Sydney, Australia |
| 08:10-08:15 |
A Verzenio EBC case study to open panel discussion Catherine Shannon, Brisbane, Australia |
| 08:15-08:30 |
Panel discussion + Q&A from audience |